Copyright
©The Author(s) 2022.
World J Virol. Sep 25, 2022; 11(5): 321-330
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.321
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.321
Table 1 Coronavirus disease 2019 disease severity score
Disease severity | Definition |
Asymptomatic | No symptoms at all during the course of COVID-19 |
Mild disease | Symptoms that did not require hospital admission; if hospitalization was required, the indication was for a cause other than the management of COVID-19 associated symptoms or signs |
Moderate disease | Symptoms that required inpatient management of COVID-19 associated symptoms, but without the need for PICU care |
Severe disease | Symptoms that required PICU care for COVID-19 related signs and symptoms |
Table 2 Characteristics of pediatric oncology patients with coronavirus disease 2019
Patient characteristics | Number | Percentage (%) |
Sex | ||
Male | 24 | 60 |
Female | 16 | 40 |
Age | ||
1-6 yr | 28 | 70 |
6-12 yr | 5 | 12.5 |
12-14 yr | 7 | 17.5 |
Primary disease | ||
Acute lymphoblastic leukemia | 30 | 75 |
Acute myeloid leukemia | 2 | 5 |
Neuroblastoma | 2 | 5 |
Rhabdomyosarcoma | 2 | 5 |
CNS tumors | 2 | 5 |
Hodgkin lymphoma | 2 | 5 |
Table 3 Laboratory and radiological details for coronavirus disease 2019 in our oncology patients
Parameters | Numbers | Percentage (%) |
WBC count | ||
Leukopenia < 4000 | 16 | 40 |
Normal WBC count | 20 | 50 |
Leukocytosis > 16000 | 4 | 10 |
Lymphocytes count | ||
Lymphopenia | 23 | 57.5 |
Normal count | 17 | 42.5 |
Lymphocytosis | 0 | 0 |
Neutrophil count | ||
Severe neutropenia | 10 | 25 |
Mild-Moderate neutropenia | 10 | 25 |
Normal count | 16 | 40 |
Neutrophilia | 4 | 10 |
CRP titer | ||
Negative < 6 | 3 | 7.5 |
Positive 6 | 37 | 92.5 |
D-Dimer | ||
Positive | 6 | 15 |
Negative | 34 | 85 |
IgG level | ||
< 700 mg/dL | 9 | 22.5 |
> 700 mg/dL | 31 | 77.5 |
Chest X-ray findings | ||
Normal chest X-ray | 18 | 45 |
Perihilar infiltrates | 12 | 30 |
Bilateral patchy consolidation | 10 | 25 |
High-resolution chest CT scan findings | ||
Bilateral infiltration > 25% | 8 | 20 |
Bilateral infiltration 25%-50% | 2 | 5 |
Bilateral infiltration > 50% | 0 | 0 |
Table 4 Details of the clinical course of coronavirus disease 2019 in oncology patients
Parameters | Number | Percentage |
Presenting symptoms | ||
Fever | 24 | 60 |
Cough | 15 | 37.5 |
Sore throat | 3 | 7.5 |
Dyspnea | 2 | 5 |
Diarrhea | 2 | 5 |
Disease severity | ||
Asymptomatic | 10 | 25 |
Mild disease | 20 | 50 |
Moderate disease | 8 | 20 |
Severe disease | 2 | 5 |
Place of care | ||
Home isolation | 12 | 30 |
COVID-19 ward | 26 | 65 |
PICU | 2 | 5 |
Treatment required | ||
No treatment | 10 | 25 |
IV antibiotic | 24 | 60 |
Azithromycin | 30 | 75 |
Vitamins | 30 | 75 |
Dexamethasone | 26 | 65 |
Oxygen support | 4 | 10 |
CPAP | 2 | 5 |
IVIG | 9 | 22.5 |
- Citation: Qatawneh MA, Altarawneh M, Alhazaimeh R, Jazazi M, Jarrah O, Shorman A, Alsadah L, Mustafa M. Manifestations of COVID-19 infection in children with malignancy: A single-center experience in Jordan. World J Virol 2022; 11(5): 321-330
- URL: https://www.wjgnet.com/2220-3249/full/v11/i5/321.htm
- DOI: https://dx.doi.org/10.5501/wjv.v11.i5.321